Clarithromycin, is a potent inhibitor of the cytochrome P450 isoenzyme CYP3A, might build the plasma concentration of statins metabolized by this pathway; therefore, increase the risk of interaction with statins in reference to pharmacokinetic studies.

Among 28,484 medicines of clarithromycin, 2317 persons were co-presented to statins. Co-organization of CYP3A4 metabolized statins and clarithromycin was connected with a 2.11 fold expanded danger of death or hospitalization (95 % certainty interim [CI]: 1.79-2.48). This impact was clarified by age, proof of cardiovascular malady, diabetes mellitus and use of different anti-infection agents (multivariable balanced danger proportion: 1.02, 95 % CI: 0.85-1.22). The affectability examinations did not change the noteworthiness of effect.

The danger for hospitalization or passing in persons accepting clarithromycin increments with age and cardiovascular disease yet is not causally connected with statin-clarithromycine co-organization.

Reference:
A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death.  Lipids Health Dis. 2015 Oct 24;14:131.